From Inhibitors to PET: SAR-Based Development of [<sup>18</sup>F]SK60 for mIDH1 Imaging

Mutations in isocitrate dehydrogenase 1/2 (mIDH1/2) are clinically significant biomarkers for diagnosis, prognosis, and therapy in cancer. To advance the noninvasive molecular imaging of mIDH1, we aim to develop a positron emission tomography (PET) radiotracer targeting IDH1R132H, the most common ty...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Sarandeep Kaur (12981271) (author)
مؤلفون آخرون:	Sladjana Dukic-Stefanovic (293331) (author), Winnie Deuther-Conrad (1399171) (author), Magali Toussaint (299906) (author), Barbara Wenzel (3079686) (author), Peter Lönnecke (1698787) (author), Cornelius K. Donat (17537085) (author), Rareş-Petru Moldovan (3069747) (author), Klaus Kopka (430828) (author)
منشور في:	2025
الموضوعات:	Biochemistry Medicine Cell Biology Pharmacology Space Science Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified reduce lipophilicity might positron emission tomography low nanomolar potency isocitrate dehydrogenase 1 developed via copper clinically significant biomarkers noninvasive molecular imaging limited brain uptake 18 </ sup radiotracer targeting idh1r132h gsk321 </ b midh1 imaging mutations sk60 </ b vivo </ vitro </ detectable brain [< sup pet imaging (< b structural modifications related therapies permeable radiometabolite performed leading novel series nonspecific binding mediated radiofluorination high selectivity high fraction common type based development
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

From Inhibitors to PET: SAR-Based Development of [<sup>18</sup>F]SK60 for mIDH1 Imaging

مواد مشابهة